Plus Therapeutics, Inc. announced on July 31, 2025, that its wholly-owned subsidiary, CNSide Diagnostics, LLC, will make the CNSide cerebrospinal fluid (CSF) assay platform and testing services commercially available in Texas in August 2025.
The initial commercial focus will be on National Cancer Institute (NCI) Designated Cancer Centers and large private healthcare systems in Texas. These include institutions such as the University of Texas - Southwestern, MD Anderson Cancer Center, and Mays Cancer Center.
CNSide is a proprietary, laboratory-developed program designed to identify tumor cells that have metastasized to the central nervous system. The platform has demonstrated high sensitivity (92%) and specificity (95%) in over 11,000 tests performed since 2020, influencing treatment decisions in over 90% of cases.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.